Background: KRAS mutations have been associated with lung metastases at diagnosis of
metastatic colorectal cancer (mCRC), but the impact of this mutation on subsequent …

Purpose: Oncogene mutations contribute to colorectal cancer development. We searched for
differences in oncogene mutation profiles between colorectal cancer metastases from …

Background KRAS mutations in colorectal cancer primary tumors predict resistance to anti-
Epidermal Growth Factor Receptor (EGFR) monoclonal antibody therapy in patients with …

Background We evaluated the association between a KRAS mutational status and various
clinicopathologic features including the metastatic pattern in patients with metastatic or …

KRAS mutant colorectal cancer (CRC) patients develop lung and brain metastases more
frequently than KRAS wild‐type (WT) counterpart. We retrospectively investigated the …

Background: KRAS mutation is a negative predictive factor for treatment with anti-epidermal
growth factor receptor antibody in metastatic colorectal cancer (CRC). KRAS mutation …

Background KRAS mutations are common in colorectal cancer (CRC). The role of KRAS
mutation status as a prognostic factor remains controversial, and most large population …

Background The purpose of the study was to evaluate whether KRAS mutation could be an
independent prognostic biomarker in patients undergoing pulmonary metastasectomy (PM) …

KRAS mutation is widely accepted as a key factor in colorectal tumorigenesis. Although
KRAS mutation is widely studied in CRC limited data are available about mutation rates and …

Background About half of metastatic colorectal cancers (CRCs) harbor Rat Sarcoma (RAS)
activating mutations as oncogenic driver, but the prognostic role of RAS mutations is not fully …